



19. TB drug treatment regimens/trials
Friday, 31 October 2014, 12:45-14:15

Chairs: TBC

Section: Tuberculosis

- OAP-344-31** **A novel five-month regimen for category II pulmonary tuberculosis patients in China: a multi-center, randomised and controlled cohort study**
 12:45-12:55
 W Sha, H Xiao, Q Zhang (*China*)
- OAP-345-31** **A randomised, 2-stage design trial of rifapentine 450mg or 600mg in place of rifampicin for intensive phase treatment of smear-positive pulmonary TB**
 12:55-13:05
 R Dawson, K Narunsky, J Hoffman, H McIlleron, A Whitelaw, K Dooley, N Gupte, S Dorman (*South Africa, USA, India*)
- OAP-346-31** **Evaluating the efficacy and safety of latent tuberculosis treatment regimens through Bayesian network analysis: a systematic review and meta-analysis**
 13:05-13:15
 D Zenner, H Stagg, R Harris, L Muñoz, I Abubakar, M Lipman (*UK, Spain*)
- OAP-347-31** **The addition of clofazimine to the first-line drug regimen leads to relapse-free cure in three months in the mouse model of tuberculosis**
 13:15-13:25
 N Ammerman, D Almeida, S Tyagi, S-Y Li, P Converse, J Grosset (*South Africa, USA*)
- OAP-348-31** **Understanding the RIFAQUIN trial: risk factors for unfavourable outcome for patients on a four-month intermittent rifapentine and moxifloxacin regimen**
 13:25-13:35
 P Phillips, M Hatherill, S Charalambous, S Mungofa, S Zizhou, J Van Dijk, J Shepherd, A Jindani (*UK, South Africa, Zimbabwe, Zambia*)
- OAP-349-31** **High dose rifampicin: a phase II trial comparing 10, 15 and 20 mg/kg rifampicin for two months**
 13:35-13:45
 M Boeree, G Kibiki, P Phillips, K Reither, S Gillespie, M Hoelscher, G Plemper Van Balen, R Aarnoutse (*Tanzania, United Rep., UK, Switzerland, Germany, Netherlands*)
- OAP-350-31** **Randomised trial of bactericidal activity of eight-weeks treatment with moxifloxacin, Pa-824 and pyrazinamide in drug sensitive & Multidrug-resistant TB**
 13:45-13:55
 D Everitt, R Dawson, A Diacon, D Burger, A Conradie, R Schall, C Van Niekerk, C Mendel (*USA, South Africa*)
- OAP-351-31** **Pharmacokinetic-pharmacodynamic analysis of an intensified regimen containing high dose rifampicin and moxifloxacin for tuberculous meningitis**
 13:55-14:05
 L Te Brake, S Dian, A.R Ganiem, C Ruesen, T.H Achmad, R Ruslami, R Van Crevel, R Aarnoutse (*Netherlands, Indonesia*)
- 14:05-14:15 Discussion